Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.8050-0.3650 (-8.75%)
At close: 04:00PM EST
3.7500 -0.06 (-1.45%)
After hours: 07:58PM EST
Advertisement
Sign in to post a message.
  • s
    schmeiser
    Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. If you want investment ideas from real knowledgeable traders, check them out at the
    https://dailytrading.tools/smpn8n platform
  • J
    Jack zeal
    People who succeed in the stock market also accept periodic losses, setbacks, and unexpected occurrences. Calamitous drops do not scare them out of the game.
  • P
    Penny
    Stephen. You are posting a lot of miss information on the post arbitration hearing. The hearing is February 1 not the fourth. There are no judges as you keep stating along with other errors. You really need to stop posting misinformation. I have direct access to the actual full court documents along with personal contact with the court clerks.
  • b
    bretscher
    The Company says that STI-9167 is unique compared to tests of EUA-approved SARS-CoV-2 antibodies in that binding and neutralization properties are maintained against the emerging omicron and omicron (+R346K) variant. Don’t even think about making another trade until you read this remarkable intraday trading book PDF for FREE... https://perfectroi.today/IntradayTrading
  • D
    Dr
    Guys, do not forget Abivertinib partnership in very short term. 61 billion $ business will not be let down by big pharma. Due crowd outside to get in most likely we will get new partner (and massive reward) in next following days....this will change Sorrento for ever. Good luck longs!
    Bullish
  • D
    Dave
    We all know who is suppressing the stock price.

    Ji is doing what he needs to do.
    1. The stock price is bring suppressed to say the least.
    2. The Board of Directors approved the financial arm to be available, for a couple of different reasons.
    a. first and foremost, protect "all" shareholders from a hostile takeover.
    b. Yes, a line of credit to tap into if need be. Call it dilution if you will, but that said, I'd much rather have it available than being pinched in a corner by intentional stock suppression or a hostile takeover.
    3. Ji and other internal stock holders have the same skin in the game as we do. Albeit, better stock options, but at any rate, they don't want the stock price to be this low either.
    4. SRNE has to be able to run the gaunlet with this many products in the pipeline. SRNE is and will be a target for a BO out takeover. If you don't believe that, you are in denial.

    God Bless and good luck to all!
  • s
    stephen
    SRNE is not a one trick pony like the others - a triple threat pipeline:

    Covid, cancer and non-opioid pain
  • D
    Don
    I am invested in Sorrento for the amazing science in Covid, cancer and non-opioid pain. Whenever the PSS settlement comes it will be nice...but for me only a side event to the upcoming revenue streams from all 3 parts of the portfolio. Great buying opportunity!
  • s
    stephen
    -Post-Hearing Submissions: After the hearing, both parties may present additional documentation, as allowed by the arbitrator.

    -The Award: Finally, the arbitrator closes the record on the case and issues a decision, including an award, if applicable the right to a jury trial against Dr. Soon-Shiong, the Company has dismissed Dr. Soon-Shiong from the related, ongoing arbitration against NantPharma, LLC.https://www.sec.gov/Archives/edgar/data/850261/000114420419017950/tv518011_ex99-1.htm

    yes there is also a lawsuit against arbitration with NantPharma not just PSS

    NantPharma arbitration IMHO is a slam dunk
  • s
    stephen
    in the arbitration settlement hearning coming feb 4 22, where a panel of 3 judges will decide the fate of PSS, typically the two sides lawyers will try to negotiate a settlement prior to the hearing to avoid a decision made by the judges where the the defendent loses control of the outcome award

    IMHO PSS lawyers will propose a settlement to SRNE prior to the Hearing date and if accepted , the hearing will close the arbitration case, if not , the panel of 3 judges will decide the fate of the fina award to SRNE IMHO

    get ready to rumble SRNE shareholders , the chase in price before the hearing begins next week guys !!!!
  • D
    Don
    When you look at the ABC10 News video, look closely at Ji, Brunswick and Royal. Do they look worried?
    No... they are happy, confident and enthusiastic!
    Why wouldn't they be? They have a nAB that deals powerfully with ALL variants-past and present. "Best-in-Class!"
    Do you think the US military might be interested?
    https://www.youtube.com/watch?v=VCmsAjRhSRI&t=2s
    In-Depth: San Diego company developing nasal drops to treat COVID
    www.youtube.com
  • s
    stephen
    feb 4 2022 arbitration hearing to decide settlement award to SRNE - stocks going to run up to feb 4 guys::

    remember judge in 2019 blocked PSS attempt to block the case from proceeding which means there is merit and only the settlement award amount is at issue IMHO

    October 15 2019 - 10:36PM
    GlobeNewswire Inc.
    Print
    Share On Facebook

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that a Los Angeles Superior Court judge has rejected Patrick Soon-Shiong’s attempt to allow him and his company, NantPharma, to avoid the billion-dollar fraud and breach of contract claims that Sorrento filed against them earlier this year. Sorrento’s claims relate to the “catch and kill” scheme that Soon-Shiong allegedly orchestrated to keep Sorrento’s promising cancer drug, Cynviloq, off the market in order to preserve Soon-Shiong’s personal financial interest in another competing drug.
    In his ruling, which was dated October 9th but was served upon Sorrento on October 15th, the Los Angeles Superior Court Judge, among other things, denied Soon-Shiong’s and NantPharma’s motion to stay or dismiss Sorrento’s arbitration against them, thus allowing the case to proceed in full. The Court also granted Sorrento’s motions to compel Soon-Shiong entity NantCell’s counterclaims to arbitration, rejecting NantCell’s attempts to avoid the arbitration agreement it had previously entered into with Sorrento.
  • s
    stephen
    On the Court's own motion, the Post-Arbitration Status Conference scheduled for 01/11/2022 is continued to 02/01/2022 at 08:45 AM in Department 14 at Stanley Mosk Courthouse.

    this is the official date for the POST arbitration status conference

    they assigned a new arbitrator since the original died unexpectantly

    but yes in next 9 days - IF the 2nd piece of the arbitration can be agreed to, its entirely possible we can hear of the settlement to be agreed to IMHO

    ie if there is two arbitrations issues being arbitrated in the same arbitration and one of the two is agreed to already it means only the 2nd arbitration issue is pending document review resolvement

    9 days to go guys , they are going run up the share price of the 2nd issue is that close to agreent with only a few pending documents to be resolved on IMHO

    but yes the death of the arbitrator moved the jan 11 to feb 1st so by now the new arbitrator and the final document review may be completed since they have assistants to the original arbitrator and it being overseen by the courts to push for conclusion

    we will see soon !!!!
  • B
    BostonLegal
    the dominant news for next week should be about two approvals in the cancer space, and something official on the pain drug. The Lee’s fast track drug approval will be overdue on February 1.
    Bullish
  • t
    tienken
    The Company says that STI-9167 is unique compared to tests of EUA-approved SARS-CoV-2 antibodies in that binding and neutralization properties are maintained against the emerging omicron and omicron (+R346K) variant.I couldn't be happier that I found https://dailytrading.tools/BTFDeBook . In the market, every trader needs an edge. Trade Ideas is my edge because it is fast, accurate and flexible. It helps me increase my profitability by quickly finding stocks that are moving and lists them in a way that allows me to decide which one I want to trade.
  • A
    Alpha C
    Fellow longs, covid products is gravy, focus on the meat balls SP102 and Abivertnib NSCLC, we can get news any day on these 2 so keep your eyes on the ball and not feed into short's short sided narrative.
    Bullish
  • A
    Ariadinvestor
    AUPH, Gold Bags although it dropped to $3.52 on 10/10/19; SRNE, Way Bigger Gold Bags. My SRNE gold bags will be fully filled with the precious mental although SRNE also has down turns like ARIA/AUPH. 🌼 Those who listen to me & accumulate the AUPH/SRNE gold bags will make big money as it's been proven that those who listened to me & accumulated ARIA have made big money. My online friend Henry listened to me, so he made big money. Mike Armato listened to me at first, so he made some small money. But Mike later married my enemy Yahoo Admin M/K.R/Sal, so he missed the Ariad buyout & lost the opportunity to make big money. $AUPH / $SRNE short squeeze matter of time! <= 🌻 I've been posting this repeatedly since 4 years ago.
    In-Depth: San Diego company developing nasal drops to treat COVID
    www.youtube.com
    Bullish
  • J
    JR
    FDA considers limiting authorizations for monoclonal antiboby treatments that are not effective against Omicron variant. Didn't Dr. Ji claim his mab works against Omicron. Can we get that approved? or is this another way for the crooked FDA/ PFE to completely ignore mabs because SRNE's mab works per Ji. I am sure they are watching the publicity SRNE is getting in San Diego.
    Bullish
  • s
    stephen
    Billionaire Los Angeles Times Owner Patrick Soon-Shiong Accused Of ‘Catch-And-Kill’ Scheme—With A Cancer Drug
    Michela Tindera
    Michela Tindera Forbes Staff

    Sorrento Therapeutics has accused billionaire Patrick Soon-Shiong of acquiring a cancer drug that would have competed with the blockbuster drug he invented and preventing it from ever reaching the market, according to a civil complaint filed in Los Angeles Superior Court on Wednesday.

    In 2015 NantPharma, a subsidiary in Soon-Shiong’s network of Nant companies, acquired the rights to the cancer drug Cynviloq from Sorrento Therapeutics with a $90 million up-front cash payment and agreed to pay an additional $1.2 billion if certain regulatory milestones were reached. At the time Cynviloq was undergoing multiple clinical trials to determine its bioequivalence to Abraxane, a cancer drug Soon-Shiong invented. In 2010 Soon-Shiong had sold the manufacturer of Abraxane, Abraxis, to Celgene in a $4.5 billion stock and cash deal.

    Sorrento’s lawsuit alleges that Soon-Shiong engaged in a “catch and kill” scheme, buying the rights to the drug but then halting the process of bringing Cynviloq to market, thereby keeping competition for Abraxane at bay. Sorrento’s complaint states that Soon-Shiong did not pursue relevant FDA approvals, let “critical patents lapse” and “demonstrated zero interest in reaching the approvals the parties had agreed upon in their sale agreement.”
  • A
    Al
    I have talked to several different doctors who all agree that antibodies are the future of medicine. SRNE has the largest library of antibodies. To read all of the bashing posts and the lowlifes who rejoice in our downward manipulated stock price disgusts me. There will be a day one of them or a loved one will need this novel form of treatment. I bet then their attitude will change.
Advertisement
Advertisement